title: Inhibitors of endothelin.
abstract: With the advent of the first generation of both selective and nonselective endothelin antagonists being a relatively recent event, the manifold therapeutic potentials of these compounds are only now being explored clinically. Undoubtedly, numerous clinical utilities for these compounds will soon be realized.
authors.affiliation: Department of Cardiovascular Biochemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-400, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Webb
authors.forename: T D
authors.initials: TD
authors.lastname: Meek
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000037:antagonists & inhibitors* / Q000145:classification / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D008967:Molecular Biology; D017466:Receptors, Endothelin / Q000145:classification / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D014018:Tissue Distribution
chemical_list: D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D017466:Receptors, Endothelin